HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Surgical treatment of nontuberculous mycobacterial lung disease.

Abstract
While the prevalence of pulmonary tuberculosis has been decreasing, the prevalence of nontuberculous mycobacterial lung disease has been increasing. Unlike tuberculosis, nontuberculous mycobacterial disease is not communicable. However, their indolent nature may result in extensive parenchymal destruction, causing respiratory failure and vulnerability to airway infection. Nontuberculous mycobacterial lung disease, therefore, has been becoming a significant health problem. According to the 2007 American Thoracic Society/Infectious Diseases Society of America statement on nontuberculous mycobacterial diseases, the primary treatment is a multidrug treatment regimen. However, its efficacy is less than satisfactory for Mycobacterium avium complex lung disease, which is the most common type of nontuberculous mycobacterial lung diseases, and for Mycobacterium abscessus lung disease, which is notoriously resistant to chemotherapeutic drugs. The statement, therefore, has proposed a multidisciplinary treatment approach for these types of nontuberculous mycobacterial lung diseases: a combination of multidrug treatment regimen and adjuvant resectional surgery. This review covers the rationale, indication, procedure, and outcome of surgical treatment of nontuberculous mycobacterial lung disease. The rationale of surgery is to prevent disease progressing by removing the areas of lung most affected, harboring the largest amounts of mycobacteria. The indications for surgery include a poor response to drug therapy, the development of macrolide-resistant disease, or the presence of a significant disease-related complication such as hemoptysis. The surgical procedures of choice are various types of pulmonary resections, including wedge resection, segmentectomy, lobectomy, or pneumonectomy. The reported series have achieved favorable treatment outcomes in surgically treated patients with acceptable morbidity and mortality rates.
AuthorsYuji Shiraishi
JournalGeneral thoracic and cardiovascular surgery (Gen Thorac Cardiovasc Surg) Vol. 62 Issue 8 Pg. 475-80 (Aug 2014) ISSN: 1863-6713 [Electronic] Japan
PMID24740640 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Bacterial Agents
Topics
  • Anti-Bacterial Agents (therapeutic use)
  • Disease Progression
  • Hemoptysis (etiology)
  • Humans
  • Male
  • Middle Aged
  • Mycobacterium Infections, Nontuberculous (complications, drug therapy, surgery)
  • Mycobacterium avium-intracellulare Infection (surgery)
  • Nontuberculous Mycobacteria (drug effects)
  • Pneumonectomy (methods)
  • Pneumonia, Bacterial (surgery)
  • Practice Guidelines as Topic
  • Respiratory Insufficiency (surgery)
  • Treatment Outcome
  • Tuberculosis, Pulmonary (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: